labetalol has been researched along with Hypertension, Malignant in 15 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Hypertension, Malignant: A condition of markedly elevated BLOOD PRESSURE with DIASTOLIC PRESSURE usually greater than 120 mm Hg. Malignant hypertension is characterized by widespread vascular damage, PAPILLEDEMA, retinopathy, HYPERTENSIVE ENCEPHALOPATHY, and renal dysfunction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sodium nitroprusside (SNP) and labetalol are recommended for the immediate treatment of malignant hypertension." | 3.79 | Central versus peripheral blood pressure in malignant hypertension; effects of antihypertensive treatment. ( Immink, RV; van den Bogaard, B; van den Born, BJ; van Lieshout, JJ; van Montfrans, GA; Westerhof, BE, 2013) |
| "Labetalol (L) was intravenously given to ten patients with an acute elevation of arterial blood pressure above to 200 to 100 mmHg." | 1.28 | [Effectiveness and hemodynamic mechanism of action of blood pressure lowering by intravenous labetalol in patients with a critical increase in blood pressure]. ( Bodmann, KF; Ehlers, B; Köhler, F; Schuster, HP, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (73.33) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| van den Bogaard, B | 1 |
| Immink, RV | 2 |
| Westerhof, BE | 1 |
| van Montfrans, GA | 2 |
| van Lieshout, JJ | 2 |
| van den Born, BJ | 2 |
| Kim, YS | 1 |
| Hollmann, MW | 1 |
| Dixit, MP | 1 |
| Hughes, JD | 1 |
| Theodorou, A | 1 |
| Dixit, NM | 1 |
| Almazov, VA | 1 |
| Bondarenko, BB | 1 |
| Shabrov, AV | 1 |
| Ram, CV | 2 |
| El Matri, A | 2 |
| Kechrid, C | 2 |
| Larabi, M | 1 |
| Belkahia, C | 2 |
| Ben Ayed, H | 2 |
| Larabi, MS | 1 |
| Kheder, A | 1 |
| Ben Maiz, H | 1 |
| Ee, B | 1 |
| Aw, TC | 1 |
| Yeo, PP | 1 |
| Teoh, PC | 1 |
| Chia, BL | 1 |
| Bisognano, JD | 1 |
| Weder, AB | 1 |
| Solomons, R | 1 |
| Cumming, AM | 1 |
| Brown, JJ | 1 |
| Lever, AF | 1 |
| Mackay, A | 1 |
| Robertson, JI | 1 |
| Schuster, HP | 1 |
| Ehlers, B | 1 |
| Bodmann, KF | 1 |
| Köhler, F | 1 |
| Ferguson, RK | 1 |
| Vlasses, PH | 1 |
| Meese, RB | 1 |
| Burris, JF | 1 |
5 reviews available for labetalol and Hypertension, Malignant
| Article | Year |
|---|---|
[Mechanism of development and principles of treatment of malignant arterial hypertension].
Topics: Adrenergic beta-Antagonists; Anemia, Hemolytic; Animals; Antihypertensive Agents; Cyclic AMP; Factor | 1983 |
Hypertensive crisis.
Topics: Antihypertensive Agents; Brain Diseases; Cerebrovascular Disorders; Clonidine; Coronary Disease; Dia | 1984 |
Effective treatment of severe hypertension.
Topics: Antihypertensive Agents; Drug Monitoring; Emergencies; Emergency Treatment; Fenoldopam; Humans; Hype | 1999 |
Hypertensive emergencies and urgencies.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; | 1986 |
Hypertensive cardiovascular emergencies.
Topics: Antihypertensive Agents; Brain Diseases; Cerebrovascular Disorders; Clonidine; Coronary Disease; Dia | 1985 |
1 trial available for labetalol and Hypertension, Malignant
| Article | Year |
|---|---|
[Usefulness of combined captopril-labetalol treatment in resistant hypertension (author's transl)].
Topics: Adolescent; Adult; Captopril; Drug Therapy, Combination; Ethanolamines; Female; Humans; Hypertension | 1982 |
9 other studies available for labetalol and Hypertension, Malignant
| Article | Year |
|---|---|
Central versus peripheral blood pressure in malignant hypertension; effects of antihypertensive treatment.
Topics: Adult; Antihypertensive Agents; Arterial Pressure; Blood Pressure; Female; Humans; Hypertension, Mal | 2013 |
Cerebral hemodynamics during treatment with sodium nitroprusside versus labetalol in malignant hypertension.
Topics: Adult; Analysis of Variance; Antihypertensive Agents; Blood Pressure Determination; Cerebrovascular | 2008 |
Hyponatremic hypertensive syndrome (HHS) in an 18-month old-child presenting as malignant hypertension: a case report.
Topics: Aldosterone; Antihypertensive Agents; Creatinine; Humans; Hypertension, Malignant; Hypertension, Ren | 2004 |
[Combined captopril and labetalol treatment of malignant arterial hypertension (author's transl)].
Topics: Adult; Captopril; Drug Synergism; Drug Therapy, Combination; Ethanolamines; Female; Heart Failure; H | 1981 |
IV. Labetalol in the management of severe hypertension.
Topics: Adult; Ethanolamines; Humans; Hypertension, Malignant; Labetalol; Middle Aged | 1981 |
Hemiparesis after single minibolus of labetalol for hypertensive encephalopathy.
Topics: Drug Administration Schedule; Epilepsy, Tonic-Clonic; Ethanolamines; Female; Hemiplegia; Humans; Hyp | 1979 |
Treatment of severe hypertension by repeated bolus injections of labetalol.
Topics: Adolescent; Adult; Aged; Angiotensin II; Blood Pressure; Creatinine; Ethanolamines; Female; Humans; | 1979 |
[Effectiveness and hemodynamic mechanism of action of blood pressure lowering by intravenous labetalol in patients with a critical increase in blood pressure].
Topics: Adult; Aged; Blood Pressure; Emergencies; Female; Heart Rate; Humans; Hypertension, Malignant; Infus | 1989 |
Hypertensive emergencies.
Topics: Antihypertensive Agents; Blood Pressure; Clonidine; Diazoxide; Emergencies; Humans; Hydralazine; Hyp | 1985 |